---
title: "Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299896103.md"
description: "Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen today and set a price target of $457.00. According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.4% and a 60.12% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Teva Pharmaceutical. In addition to Piper Sandler, Amgen also received a Buy from Scotiabank’s Louise Chen in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Amgen (NASDAQ: AMGN)."
datetime: "2026-09-23T12:25:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299896103.md)
  - [en](https://longbridge.com/en/news/299896103.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299896103.md)
generator: "portal-rs"
---

# Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen today and set a price target of $457.00.

According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.4% and a 60.12% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Teva Pharmaceutical.

In addition to Piper Sandler, Amgen also received a Buy from Scotiabank’s Louise Chen in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Amgen (NASDAQ: AMGN).

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [BNS.US](https://longbridge.com/en/quote/BNS.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)

## Related News & Research

- [How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story](https://longbridge.com/en/news/300175029.md)
- [Amgen reports a Phase 3 win with Sjögren’s drug candidate](https://longbridge.com/en/news/300046755.md)
- [Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data](https://longbridge.com/en/news/299801248.md)
- [Amgen Announces Positive Topline Phase 3 Results For Dazodalibep In Sjogren's Disease](https://longbridge.com/en/news/299775087.md)
- [Amgen's autoimmune drug succeeds in late-stage trial](https://longbridge.com/en/news/299770733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**